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An accurate evaluation of the Her-2 status has important prognostic and therapeutic implications in many carcinomas. The aim
of the study was to correlate Her-2 locus (17q11.2) ampliﬁcation and chromosome 17 gains as assessed by ﬂuorescent in situ
hybridization (FISH) with Her-2 protein overexpression by immunohistochemistry (IHC) in patients with Barrett’s esophagus
(BE)andesophagealadenocarcinoma(EAC).Weanalyzed34patientswithHer-2 ampliﬁcationand/orchromosome17gainsusing
FISH on brush cytology specimens. Seven patients (21%) showed high Her-2 locus ampliﬁcation (Her-2:C e p 1 7≥ 5:1), 5 (15%)
showed low Her-2 locus ampliﬁcation (Her-2:C e p 1 7≥ 2 < 5:1), and 22 (65%) displayed gains of chromosome 17 only. Further,
we conﬁrmed Her-2 ampliﬁcation on corresponding biopsies that were taken at the same occasion as the cytologybrushings.
Then, we compared the FISH results with IHC data obtained from the corresponding biopsies and showed that low level of Her-2
ampliﬁcation does not correlate with Her-2 protein overexpression (score +3/+2;P = 1),incontrastto thehigh ampliﬁcation level
(P = .001). Thus, in our population of BE and EAC patients, low level of Her-2 ampliﬁcation does not result in detectable level of
Her-2 protein as assessed by IHC.
1.Introduction
Barrett’s esophagus (BE) is a premalignant condition of the
distal esophagus that is associated with an increased risk
of developing esophageal adenocarcinoma (EAC) [1, 2]. In
recentyears,theincidenceofBEandEAChasbeenincreasing
dramatically and death from EAC has become a major
problem [1, 3]. Since long-term survival of EAC patients is
highlydependentonearlydiagnosis,detectionofBEpatients
at high risk for malignant progression has become crucial
[4]. The present endoscopic and histopathologic surveillance
of BE patients have been proven to be insuﬃcient for
eﬀectiveidentiﬁcationofhigh-riskpatients[5–7].Evaluation
ofobjective,molecularmarkersmayleadtoabetterrationale
for surveillance programs, as well as, targeted therapeutic
strategies.
Her-2(neu) is a proto-oncogene localized on chromo-
some 17q, which encodes for a transmembrane tyrosine
kinase growth factor receptor (Her-2/c-erB-2) [8]. Ampliﬁ-
cation of the Her-2 gene and Her-2 protein overexpression
has been studied in many malignancies, but most extensively
in breast cancer and its precursor lesions [9]. In breast
cancer, Her-2 overexpression has been correlated with poor
prognosis or a lack of response to chemotherapy [10, 11].
However, with the antibody-based (Tastuzumab/Herceptin)
therapeutic approach as an adjunctive treatment for Her-2
positive breast cancer patients, the prognosis of this patient
group has signiﬁcantly improved [12, 13].2 Journal of Oncology
Her-2 ampliﬁcation and its protein overexpression have
also been reported in dysplasia and EAC associated with
BE. Several immunohistochemical studies on BE, suggest
that Her-2 protein overexpression is a frequent and early
event [14, 15], whereas others indicate that it is much
less common and occurs late during the process of BE
progression into EAC [16, 17]. Most of the studies that
investigatedHer-2 geneampliﬁcationdescribethisasarather
late event in BE progression, which is present only in HGD
and EAC cases [18, 19], while some indicate that Her-2
ampliﬁcation can already be seen in LGD [20]. Thus, the
association of Her-2 gene ampliﬁcation and Her-2 protein
overexpression during the process of BE progression is
still unclear. Moreover, there seems to be an important
discrepancy between results from immunohistochemistry
(IHC) and gene ampliﬁcation studies for determining Her-2
status. An accurate detection of the Her-2 status may help to
identify high-risk subpopulations in BE surveillance cohorts,
and to select for those EAC patients who may beneﬁt from
Her-2-targeted therapies [21].
The most widely used assays to determine Her-2 status
is immunohistochemistry (IHC) for the detection of protein
overexpression, and DNA ﬂuorescent in situ hybridization
(FISH) for assessing the locus copy number. Although,
IHC staining is the predominant method utilized, it can
be signiﬁcantly aﬀected by technical issues, that is, tissue
ﬁxation, speciﬁcity of the antibody, and variation in quan-
tiﬁcation and interpretation of the intensity of the staining
[22, 23]. DNA-FISH is not as widely available as IHC since it
requires appropriate equipment and optimization for each
tissue type, but, it is quantitatively accurate and highly
reproducible [24]. This technique can be successfully applied
on both archival paraﬃn biopsies [19, 20, 25]a n do nb r u s h
cytology samples [26, 27]. The important advantages of
applying brush cytology to BE patients includes simplicity,
lower cost, and the potential to sample a larger area
of the BE epithelium when compared to taking random
biopsies. Cytology samples are also more reliable for the
enumeration of FISH signals, since there is no artifact caused
bynucleartruncationasisthecasewhenusingtissuesections
[28].
Recently, we have evaluated the frequency of Her-2 locus
and chromosome 17 abnormalities using DNA-FISH on
brush cytology specimens of BE patients with diﬀerent stages
of dysplasia [27]. The aim of the present study was to
compare the Her-2 locus ampliﬁcation and/or chromosome
17 gains as determined by DNA-FISH on BE/EAC brush
cytology specimens to Her-2 protein overexpression as
assessed by IHC on corresponding biopsies that were taken
at the same time as the brush cytology specimens.
2.MaterialsandMethods
2.1. Patients. A total of 34 of BE patients showing Her-
2/chromosome 17 abnormalities were included in this
study. Out of these 34 cases, 22 patients showed gain of
chromosome 17, and 12 patients had gain of chromosome
17 and/or Her-2 locus ampliﬁcation. The cases were either
retrieved from our previous DNA-FISH surveillance study
on brush cytology specimens [27] or from an ongoing study
in which EAC patients are screened for Her-2 ampliﬁcation
status by DNA-FISH. The patients underwent endoscopy at
the Academic Medical Center in Amsterdam between 2002
and 2009. During endoscopy, brush cytology specimens
and corresponding biopsies were taken for FISH, IHC, and
histopathological analysis. In case of BE, the biopsies were
taken at least per 2cm in 4 quadrants and of all suspected
visible lesions using the protocol of Reid et al. [29]. In the
EAC cases, biopsies were taken from the mass, and if present
also from the adjacent Barrett’s mucosa. All BE patients were
on long-term proton pump inhibition of 40 to 80mg daily
to prevent reﬂux esophagitis. The Ethics Committee of the
Academic Medical Center approved the study. All patients
signed informed consent for the use of their biopsy and
brush cytology material.
2.2. Brush Cytology. Cytological brush material was sampled
using the Wilson-Cook (Winston-Salem, NC) brush type
LCB-220-3-1.5-S as described previously [27]. From the cell
suspension obtained from brushing a single layer of the cells
on a glass slide was generated using the Cytospin (Shandon
Cytospin 4 Cytocentrifuge, Thermo, Waltham, MA). The
cytospin procedure was performed as described previously
[27]. After the procedure the cytospin slides were dried at
RT, and then stored at −80◦C.
2.3. Fluorescent In Situ Hybridization (FISH) on Brush Cytol-
ogy and Tissue Samples. Dual color probe was used combin-
ingchromosomalcentromericprobe(CEP)forchromosome
17 SpectrumGreen with the locus speciﬁc probe (LSI)
for Her-2 (17q11.2-q12) SpectrumOrange (Vysis, Downers
Grove, IL). DNA-FISH on brush cytology was performed
as described previously [27]. Additionally, DNA tissue FISH
was preformed in the subset of the patients, to determine
correlation between abnormalities as assessed by FISH on
brush cytology and tissue samples [30].
2.4. Scoring of FISH Signals. As described previously, after
the FISH procedure, 100 to 200 interphase nuclei of BE
cells were scored per slide by an experienced scorer (A.
M. Rygiel) using Olympus BX61 ﬂuorescent microscope
(Germany) [27]. The cases were evaluated without prior
knowledge of histology ﬁndings. Damaged cells and cells
with indistinct and blurry signals were excluded from the
analysis. The categories of Her-2 locus abnormalities were
determined by calculating the ratio of Her-2 locus signals
(red) to CEP17 signals (green) as described previously [31].
The following categories were distinguished: A ratio <2w e r e
considered as having no ampliﬁcation, ratio’s ≥2a n d<5
were considered as a low ampliﬁcation, and ratio ≥5w a s
considered as a high ampliﬁcation. More then two green
signals (CEP 17) accompanied by the same number of red
signals (Her-2 locus) was considered to be indicative of gain
of chromosome 17 (ratio 1:1). Following these criteria the
cases were classiﬁed as displaying a gain of chromosome
17 and a low-or high-level ampliﬁcation of Her-2 locusJournal of Oncology 3
(cutoﬀ ≥3% of abnormal nuclei). The cutoﬀ value was
obtained from counts in the normal squamous epithelium
taken from 20BE patients without dysplasia and calculated
as the mean percentage of squamous nuclei with signal gain
plus 3xSD (standard deviation) as described previously [27].
2.5. Immunohistochemistry (IHC). Immunohistochemistry
(IHC) was performed on archival material from paraﬃn
embedded tissue obtained during the same endoscopy
procedure as the brush cytology. IHC for Her-2 protein
(antibodies/Her-2/neu/c-erbB-2 Ab-17 clone e2-4001+ 3 B5,
mouse monoclonal, Neomarkers, Stratech Scientiﬁc Ltd,
Cambridgeshire,UK)wasperformedaccordingtoastandard
IHC protocol. Brieﬂy, paraﬃns e c t i o n sw e r ed e p a r a ﬃnised
and rehydrated in graded alcohols. Endogenous peroxidase
activity was quenched with 0.3% hydrogen peroxide in
methanol for 20 minutes and then washed (3 × 5m i n u t e s
in PBS). Antigen retrieval was performed by boiling slides
for 10 minutes in 0.01M Sodium Citrate Ph 6.0. Nonspeciﬁc
binding sites were blocked with 5% goat serum in PBS
for 10 minutes, and then washed (3 × 5 minutes in PBS).
Slides were incubated with the primary antibodies diluted
1:2000 in Normal Antibody Diluent (Scytek, Logan, Utah,
USA) for 60 minutes. After washing (3 × 5 minutes in PBS),
postantibody blocking solution (Immunologic, Duiven, The
Netherlands) diluted 1:2 in PBS was applied for 15 minutes.
After washing (3 × 5 minutes in PBS), slides were then
incubated with biotinylated secondary antibodies diluted
1:2 in PBS (Poly-HRP-Goat anti Mouse IgG, Immunologic)
at room temperature for 30 minutes. Slides were washed
(3 × 5 minutes in PBS), and then the peroxidise activity was
detected with “Fast DAB” (3,3
 -diaminobenzidine, Sigma,
St Louis, MO) with 0.05% hydrogen peroxide. Finally,
sections were counterstained with Mayer’s haematoxylin,
dehydrated and mounted with Pertex under cover slips.
Her-2 protein expression was evaluated by an experienced
pathologist (F. J. ten Kate) according to the scoring system
recommended by the DACO HercepTest. No staining at
all or membrane staining in <10% of the epithelial cells
was considered negative (score 0). Faint or barely per-
ceptible, incomplete membrane staining in >10% of the
epithelial cell was scored +1. Weak to moderate staining
of the entire membrane in >10% of the epithelial cells
was scored +2, and strong staining of the entire mem-
brane in >10% of the epithelial cells resulted in a score
+3.
2.6. Statistical Analysis. Diﬀerences in frequencies were
tested using a Fisher’s exact test (2-sided) and statistical
signiﬁcance was set at a P-value of <.05. The statistical
analyses were conducted using SPSS software (version 12.0;
SPSS, Inc, Chicago, IL).
3. Results
3.1. Patients. Of the 34 cases included in this study, 31 were
male and 3 female with a median age of 60 (range 26–84).
In the BE cases, the median BE length was 6cm (range
1–13cm). These BE cases included 4 patients with ND, 5
patients with IND or LGD, and 13 patients with HGD. There
were 12 patients with EAC. Nine out of the 12 EAC patients
were staged according to the Union International Control
Center TNM system. The EAC patients included 5 cases
with T1/T2N0M0, 2 cases with T3N0M0, and 2 cases with
T3N1M0 stage.
3.2. Chromosome 17 and Her-2 Locus Copy Number as
Assessed by FISH on Brush Cytology Samples. Twenty two
patients (4 ND, 5 IND/LGD, 4 HGD, and 9 EAC) displayed
gainsofchromosome17and12patients(9HGDand3EAC)
showed Her-2 locus ampliﬁcation. Of the 12 cases with the
Her-2 locus ampliﬁcation 5 patients (41%) displayed a low
level, and 7 patients (58%) a high level of the Her-2 locus
ampliﬁcation.
3.3. Conﬁrmation of the FISH Results as Found in the Brush
Cytology Specimens on Corresponding BE Biopsy Samples. In
seven cases with Her-2 locus ampliﬁcation detected in the
cytology samples, FISH was also performed on biopsies that
were taken at the same occasion as the cytology brushings.
Three cases showed a low level of Her-2 locus ampliﬁcation
and 4 cases displayed a high level of the ampliﬁcation. In
all seven cases the ampliﬁcations as found in the cytology
specimens were also seen in the corresponding biopsy
samples (Table 1).
3.4. Correlation between Chromosome 17 and Her-2 Locus
Copy Numbers by FISH on Brush Cytology and Her-2 Overex-
pression as Determined by IHC on Biopsies. The comparison
between chromosome 17 status, the levels of Her-2 locus
ampliﬁcation, and Her-2 protein overexpression is presented
in Tables 1 and 2. Of the 7 cases with a high level of Her-
2 ampliﬁcation, 5 (72%) showed strong overexpression of
the protein (+3), and two cases (28%) showed moderate
or faint Her-2 overexpression (+1/+2). Of the 5 patients
displaying a low level of Her-2 ampliﬁcation, only one case
(20%) showed moderate Her-2 overexpression (+2) while
the rest were negative for protein overexpression. Of the 22
cases with gain of chromosome 17, 3 cases (14%) showed
moderate Her-2 overexpression (+2), whereas the remaining
casesshowedfaintornostainingoftheHer-2protein(0/+1).
Statistical analysis showed that there is a signiﬁcant
diﬀerence between low levels and high levels of Her-2 locus
ampliﬁcation with respect to Her-2 protein overexpression
as detected by IHC (P = .028). When we compared Her-2
ampliﬁed cases to cases with no ampliﬁcation, we found that
only a high level of the ampliﬁcation correlates with strong
or moderate overexpression of the Her-2 protein (P = .001).
Incontrast,thereisnocorrelationbetweenlowampliﬁcation
of the Her-2 locus and Her-2 protein overexpression (P = 1;
Table 2).
4. Discussion
It is generally believed that Her-2 locus ampliﬁcation is
always coupled with strong Her-2 protein overexpression,4 Journal of Oncology
Table 1: Her-2 protein overexpression and Her-2 locus/chromosome 17 status in BE and EAC cases.
No. Histology IHC Brush cytology FISH Tissue FISH
Her-2 expression Her-2 locus ampliﬁcation CEP17 Her-2 locus ampliﬁcation CEP17
91 ND 0 — Gain Nd Nd
237 ND 0 — Gain Nd Nd
75 ND 0 — Gain Nd Nd
148 ND 0 — Gain Nd Nd
59 IND 1 — Gain Nd Nd
134 IND 0 — Gain Nd Nd
273 IND 1 — Gain Nd Nd
98 LGD 0 — Gain Nd Nd
255 LGD 0 — Gain Nd Nd
3 HGD 0 — Gain Nd Nd
4 HGD 3 High (50) Gain (42) High (39) Gain (13)
5 HGD 0 Low (5) Gain (71) Low (10) Gain (59)
152 HGD 0 — Gain Nd Nd
167 HGD 1 High (8) Gain (13) Nd Nd
170 HGD 2 Low (11) — Nd Nd
173 HGD 3 High (50) Gain (23) Nd Nd
193 HGD 0 Low (90) Gain (6) Low (55) —
202 HGD 3 High (75) Gain (83) High (79) Gain (84)
211 HGD 2 High (6) Gain (11) High (34) Gain (34)
235 HGD 0 — Gain Nd Nd
236 HGD 1 Low (20) Gain (13) Low (10) Gain (53)
247 HGD 2 — Gain Nd Nd
264 EAC 1 — Gain Nd Nd
265 EAC 2 — Gain Nd Nd
270 EAC 0 — Gain Nd Nd
223 EAC 0 Low (8) Gain Nd Nd
232 EAC 1 — Gain Nd Nd
233 EAC 2 — Gain Nd Nd
251 EAC 1 — Gain Nd Nd
254 EAC 0 — Gain Nd Nd
200 EAC 3 High (82) — Nd Nd
274 EAC 0 — Gain Nd Nd
276 EAC 3 High (50) Gain (63) High (42) Gain (42)
250 EAC 0 — Gain Nd Nd
FISH—ﬂuorescent in situ hybridization; (—) indicates absence of certain abnormality; (gain)—ratio 1:1 of Her-2: Cep17, the number of signals in diﬀerent
cases varied from 3 to 6 signals per cell; (low)—low level ampliﬁcation—ratio ≥ 2 < 5:1o fHer-2: Cep17; (high)—high level ampliﬁcation—ratio ≥5:1of
Her-2: Cep17; in the brackets % of abnormal cells
IHC—immunohistochemistry; IHC score 0—no staining, IHC score +1—faint staining, IHC score +2—moderate staining, IHC score +3—strong staining;
ND—no dysplasia; IND—indeﬁnite for dysplasia; LGD—low grade dysplasia; HGD—high grade dysplasia.
Table 2: Frequencies of Her-2 protein overexpression in BE/EAC patients with respect to high and low levels of Her-2 locus ampliﬁcation
versus no ampliﬁcation (Cep17 gain).
FISH IHC P∗
0/+1 +2/+3
No./total No. (%)
No ampliﬁcation (Cep 17 gain) 19/22 (86) 3/22 (14) .001
Her-2 high ampliﬁcation 1/7 (14) 6/7 (86)
No ampliﬁcation (Cep17 gain) 19/22 (86) 3/22 (14) 1
Her-2 low ampliﬁcation 4/5 (80) 1/5 (20)
FISH—ﬂuorescent in situ hybridization, IHC—immunohistochemistry, ∗Fisher exact test.Journal of Oncology 5
(a) (f)
(b) (g)
(c) (h)
(d) (i)
(e) (j)
Figure 1: Her-2 protein and Her-2 locus status as determined by IHC on BE biopsy and FISH on BE brush cytology specimens. (a) Strong
overexpression of Her-2 protein (+3) in HGD, (b) moderate overexpression of Her-2 protein (+2) in EAC, (c) no overexpression of Her-2
protein (score 0) in EAC, (d) no overexpression of Her-2 protein (score 0) in LGD, (e) no overexpression of Her-2 protein (score 0) in ND,
(f) high level of Her-2 locus ampliﬁcation (clusters) in a cytology sample of a HGD case—CEP 17 (green) and Her-2 locus (red), (g) gain
of chromosome 17 in a cytology sample of an EAC case—CEP 17 (green) and Her-2 locus (red), (h) low level of Her-2 ampliﬁcation (ratio
≥ 2 < 5: 1 o f Her-2: Cep17) in a cytology sample of an EAC case, CEP 17 (green) and Her-2 locus (red), (i) gain of chromosome 17 in
a cytology sample of a LGD case—CEP 17 (green) and Her-2 locus (red), and (j) two copies of chromosome 17 (disomy) and Her-2 locus
(normal pattern) in a cytology sample of a ND case—CEP 17 (green) and Her-2 locus (red).6 Journal of Oncology
while gains of chromosome 17 usually do not result in
Her-2 protein overexpression [19, 20, 32, 33]. For most
cancers, daily practice is to use IHC to determine Her-2
overexpression, and in case of positive IHC staining, FISH
is applied to conﬁrm gene ampliﬁcation. This is generally
done to rule out false positive staining by IHC. In BE and
EAC it is, however, not clear whether this set up would
be suitable to identify all patients with abnormal Her-2
gene status. Therefore, in this study, we were interested in
the miss rate (false negativity) of IHC to detect cases with
Her-2 locus ampliﬁcations as assessed by FISH. Hereto, we
correlated Her-2 locus ampliﬁcation and/or chromosome 17
gains with Her-2 protein overexpression in BE and EAC
cases. We found important diﬀerences between the level of
Her-2 locus ampliﬁcation and Her-2 protein overexpression.
We demonstrated that low levels of Her-2 ampliﬁcation
(ratio of Her-2:C e p 1 7 ≥ 2 < 5:1 ) d o n o t c o r r e l a t e
with IHC (P = 1), in contrast to high ampliﬁcation
levels (ratio of Her-2:C e p 1 7 ≥ 5 : 1), which shows a
signiﬁcant correlation with Her-2 protein overexpression
(P = .001).
The majority of our cases (5/7, 72%) with a high level of
theHer-2 locusampliﬁcationinthebrushcytologyspecimen
showed strong protein overexpression (+3 score) in the
biopsy specimen, which is in agreement with literature data
showing a high correlation between IHC +3 staining and
ampliﬁcations detected by FISH [31, 34]. However, two of
ourHGDcaseswithhighlevelofHer-2 ampliﬁcationshowed
faint or moderate Her-2 overexpression. This discordance
may be due to heterogeneity of the lesion or to the subjective
interpretation of the staining intensity [23].
More importantly, we demonstrated that a low level
of Her-2 locus ampliﬁcation did not result in strong (+3)
Her-2 overexpression, while moderate (+2) Her-2 staining
was seen in only one case. One could argue that this
ﬁnding may be due to our methodology, since we applied
DNA-FISH on brush cytology samples and compared these
results to IHC on biopsy specimens. Theoretically, in
case of tumor heterogeneity, random biopsies may have
missed areas with the Her-2 locus ampliﬁcation due to
sampling errors, while brush cytology in principal samples
the whole or the majority of the BE surface and may
give a better representation of the diﬀerent cellular clones
that may coexist in BE [35]. To investigate whether the
discrepancy between the Her-2 locus ampliﬁcation in the
cytology specimens and IHC on biopsies was due to
sampling errors when taking biopsies, we also performed
FISH on the biopsies in several cases. In all these cases,
we were able to conﬁrm the Her-2 locus ampliﬁcation in
the corresponding biopsy sample. Therefore, our results
are very unlikely to be due to a bias caused by biopsy
sampling errors. Besides, our ﬁnding is in agreement with
literature data. A similar discordance between low levels
of Her-2 ampliﬁcation and protein overexpression was also
found in ovarian tumors comparing IHC with FISH on
biopsy samples [34]. Moreover, studies on breast cancer
compared IHC with FISH, and demonstrated that only
a minority of cases (3%–7%) with low levels of Her-2
ampliﬁcation show protein overexpression [36–38]. This
indicates that in general DNA-FISH seems to be a more
sensitive technique then IHC to detect low levels of Her-2
gene status changes. As expected, we found that the majority
of our cases (86%) with gains of chromosome 17 only,
showed no Her-2 protein overexpression, while three of
these cases (14%) showed moderate overexpression. These
observations are consistent with studies evaluating Her-2
status by IHC and FISH on BE/EAC tissue sections, showing
moderate (+2) Her-2 protein overexpression in some cases
but no association with strong (+3) overexpression [19,
20]. Thus, our results actually indicate that the levels of
Her-2 protein as a result of low Her-2 locus ampliﬁcation
and gains of chromosome 17 are in general too low for
detection by IHC, while FISH accurately can detect these
cytogenetic abnormalities. This is probably because FISH, as
demonstrated in breast cancer studies, is quantitatively accu-
rateandveryreproducible[24]. Another explanation may be
that particularly in cases with low level of Her-2 status, gene
transcription and posttranscriptional or posttranslational
events could be down-regulated or abnormal, ultimately
leading to low Her-2 protein levels or abnormal epitope
production. Alternatively, tissue preservation could have
been insuﬃcient, leading to protein degradation resulting in
faint or negative staining.
So far, there is no consensus with regard to the optimal
test for Her-2 assessment. Although, IHC staining is the
predominant method utilized, it can be signiﬁcantly aﬀected
by technical issues, especially in archival ﬁxed paraﬃn
tissues, resulting frequently in false positive results since the
scores are based on staining intensity [39]. Therefore, in
breast cancers it is strongly recommended that IHC +2 cases
are conﬁrmed by FISH for a more appropriate selection of
candidate patients for targeted therapy, for instance with
the anti Her-2 monoclonal antibody Trastuzumab [36]. In
our set up, however, we were able to show that IHC gives
false negative results mostly in cases with low level of Her-2
ampliﬁcation. In this respect, it is important to realize that
low levels of Her-2 ampliﬁcation in breast cancer is regarded
as an indication for immunotherapy with Trastuzumab [40].
Moreover, it is expected that in the upcoming era BE patients
with Her-2 positive esophageal adenocarcinomas will also
beneﬁt from this therapy and the ﬁrst phase I/II trials have
been already published [21, 41].
In summary, we showed that DNA-FISH on brush
cytology samples is a representative and useful diagnostic
tool, which at least in cases with low level of the Her-2
locus ampliﬁcation, is superior to IHC on biopsy. Although
more studies with larger sample size need to be performed
to conﬁrm our ﬁndings, we suggest that FISH should be
the ﬁrst method of choice for accurate detection of Her-2
status in BE and EAC patients. This is of importance since
an accurate assessment of Her-2 status in BE associated EAC
andothermalignanciesishighlyrelevantforproperselection
of patients that are eligible for treatment with Trastuzumab
or other Her-2 targeted molecular strategies.Journal of Oncology 7
Abbreviations
ND: no dysplasia
LGD: low grade dysplasia
HGD: high grade dysplasia
EAC: esophageal adenocarcinoma
FISH: ﬂuorescent in situ hybridization
IHC: immunohistochemistry.
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